Status:
COMPLETED
Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis Enhance Chemical Pleurodesis
Lead Sponsor:
Memorial Healthcare System
Collaborating Sponsors:
Genentech, Inc.
Conditions:
Pleural Effusion
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
Prospective Randomized Double-Blind Controlled Trial of Intrapleural Fibrinolytic Therapy to Enhance Chemical Pleurodesis versus Standard of care Talc therapy in patients with recurrent pleural effusi...
Detailed Description
This protocol describes a prospective, randomized, double-blind controlled trial comparing TSP alone to the combination of TSP with cathflo activase for achieving optimal results with pleurodesis for ...
Eligibility Criteria
Inclusion
- Age \> 18 years
- Symptomatic pleural effusion requiring intervention
- Expected survival \> 3 months
- Written informed consent to trial participation
Exclusion
- Females who are pregnant or lactating
- Inability to obtain consent from the patient or patient's designated representative.
- Inability of the patient to comply with the protocol.
- Previously documented adverse reaction to talc or cathflo activase.
- Oral or intravenous steroid therapy
Key Trial Info
Start Date :
June 15 2021
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 14 2023
Estimated Enrollment :
27 Patients enrolled
Trial Details
Trial ID
NCT04806373
Start Date
June 15 2021
End Date
December 14 2023
Last Update
June 8 2025
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Healthcare System
Hollywood, Florida, United States, 33021